Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device Accessories, 40315-40316 [2016-14562]
Download as PDF
40315
Federal Register / Vol. 81, No. 119 / Tuesday, June 21, 2016 / Notices
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Description and 21 CFR section
FDA form No.
Total hours
Registrations or Updates, § 118.11 ...
Cancellations, § 118.11 ......................
Form FDA 3733 2
Form FDA 3733 ...
300
30
1
1
300
30
2.3
1
690
30
Total ............................................
..............................
........................
........................
........................
........................
720
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
term ‘‘Form FDA 3733’’ refers to both the paper version of the form and the electronic system known as the Shell Egg Producer Registration Module, which is available at https://www.access.fda.gov per § 118.11(b)(1).
2 The
This estimate is based on the average
number of new shell egg producer
registrations and cancellations received
in the past 3 years under § 118.11. We
estimate that we will receive an average
of 300 registrations or updates per year
over the next 3 years. Based on the
number of cancellations previously
received, we estimate that we will
receive approximately 30 cancellations
per year over the next 3 years.
We estimate that it takes the average
farm 2.3 hours to register, taking into
account that some respondents
completing the registration may not
have readily available Internet access.
Thus, the total annual burden for new
shell egg producer registrations or
updates is calculated to be 690 hours
(300 × 2.3 hours).
We estimate cancelling a registration,
on average, requires a burden of
approximately 1 hour, taking into
account that some respondents may not
have readily available Internet access.
Thus, the total annual burden for
cancelling shell egg producer
registrations is calculated to be 30 hours
(30 cancellations × 1 hour).
Dated: June 15, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–14584 Filed 6–20–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
asabaliauskas on DSK3SPTVN1PROD with NOTICES
[Docket No. FDA–2016–N–1593]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Device
Accessories
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
SUMMARY:
VerDate Sep<11>2014
18:37 Jun 20, 2016
Jkt 238001
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(the PRA).
DATES: Fax written comments on the
collection of information by July 21,
2016.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
title ‘‘Medical Device Accessories.’’ Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Medical Device Accessories—OMB
Control Number 0910–NEW
The draft guidance encourages
manufacturers and other parties to
utilize the process defined in section
513(f)(2) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) to request
risk- and regulatory control-based
classifications of new types of
accessories. This process provides a
pathway to class I or class II
classification for accessory devices for
which general controls, or general and
special controls, provide a reasonable
assurance of safety and effectiveness,
but for which there is no legally
marketed predicate device.
In accordance with section 513(f)(2) of
the FD&C Act, manufacturers and other
parties may submit a de novo requesting
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
FDA to make a classification
determination for the accessory device
according to the criteria in section
513(a)(1) of the FD&C Act. The de novo
must include a description of the device
and detailed information and reasons
for any recommended classification (see
section 513(f)(2)(A)(v) of the FD&C Act).
In the Federal Register of January 20,
2015 (80 FR 2710), FDA published a 60day notice requesting public comment
on the proposed collection of
information. We received a total of 12
comments on the guidance. Of these the
following were related to the
information collection:
Two comments raised concerns
regarding the possible difficulties for
manufacturers to submit a de novo for
new accessories and for risk- and
regulatory control-based classification of
accessories that were approved under
the premarket approval application
(PMA) for the parent medical devices.
One comment questioned whether FDA
considered the possible ‘‘practical and
economic impact’’ of the proposed
definition of ‘‘accessories’’ that may
result in manufacturers being obligated
to list some components as accessories
for FDA’s registration and listing
process. The second comment
anticipates that ‘‘few companies are
likely to pursue this route given the
associated costs and minimal advantage
in time to market.’’ Neither comment
specifically discusses the potential PRA
burden hours of voluntarily submitting
a de novo application; however, it may
be inferred that this could impact their
resources under the PRA for submitting
a de novo.
Also, FDA is not proposing to limit or
remove any mechanism that currently
exists for manufacturers to obtain
marketing authorization for accessories.
De novos are typically less burdensome
than PMAs for the purpose of
classifying a new accessory.
Furthermore, if a manufacturer wishes
for an accessory to remain in the same
regulatory class as the parent device,
that manufacturer may continue to
submit the accessory for clearance or
E:\FR\FM\21JNN1.SGM
21JNN1
40316
Federal Register / Vol. 81, No. 119 / Tuesday, June 21, 2016 / Notices
approval under the submission type
applicable to the parent device.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
Accessory classification de novo request ............................
8
1
8
180
1,440
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Respondents are medical device
manufacturers seeking to market device
accessories. Of the approximately 41 de
novo applications received per year,
only 2 have been associated with
accessories. With heightened awareness
of the availability of the de novo
pathway for accessories, we expect to
receive four to six additional accessories
applications per year. Therefore, we
estimate that we will receive
approximately eight accessory
classification de novo requests per year.
Based on estimates by FDA
administrative and technical staff who
are familiar with the proposed
submission process for accessory
classification requests and on our
burden estimate for a similar
information collection request (see ‘‘De
Novo Classification Process Evaluation
of Automatic Class III Designation; Draft
Guidance for Industry and Food and
Drug Administration Staff;
Availability,’’ 79 FR 47651 at 47653,
August 14, 2014), we estimate that the
submission process for each accessory
classification request will take
approximately 180 hours.
The draft guidance also refers to
previously approved collections of
information found in FDA regulations.
The collections of information in 21
CFR parts 801 and 809 have been
approved under OMB control number
0910–0485; the collections of
information in 21 CFR part 807, subpart
E have been approved under OMB
control number 0910–0120; the
collections of information in 21 CFR
part 814 have been approved under
OMB control number 0910–0231; and
the collections of information in 21 CFR
part 860, subpart C, have been approved
under OMB control number 0910–0138.
Dated: June 15, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–14562 Filed 6–20–16; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
18:37 Jun 20, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–E–2335]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; XOFIGO
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) has determined
the regulatory review period for
XOFIGO and is publishing this notice of
that determination as required by law.
FDA has made the determination
because of the submission of an
application to the Director of the U.S.
Patent and Trademark Office (USPTO),
Department of Commerce, for the
extension of a patent which claims that
human drug product.
DATES: Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by August 22, 2016.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
December 19, 2016. See ‘‘Petitions’’ in
the SUPPLEMENTARY INFORMATION section
for more information.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2014–E–2335 for ‘‘Determination of
Regulatory Review Period for Purposes
of Patent Extension; XOFIGO.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
E:\FR\FM\21JNN1.SGM
21JNN1
Agencies
[Federal Register Volume 81, Number 119 (Tuesday, June 21, 2016)]
[Notices]
[Pages 40315-40316]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-14562]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-1593]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Medical Device
Accessories
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995 (the PRA).
DATES: Fax written comments on the collection of information by July
21, 2016.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-NEW and
title ``Medical Device Accessories.'' Also include the FDA docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Medical Device Accessories--OMB Control Number 0910-NEW
The draft guidance encourages manufacturers and other parties to
utilize the process defined in section 513(f)(2) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) to request risk- and regulatory
control-based classifications of new types of accessories. This process
provides a pathway to class I or class II classification for accessory
devices for which general controls, or general and special controls,
provide a reasonable assurance of safety and effectiveness, but for
which there is no legally marketed predicate device.
In accordance with section 513(f)(2) of the FD&C Act, manufacturers
and other parties may submit a de novo requesting FDA to make a
classification determination for the accessory device according to the
criteria in section 513(a)(1) of the FD&C Act. The de novo must include
a description of the device and detailed information and reasons for
any recommended classification (see section 513(f)(2)(A)(v) of the FD&C
Act).
In the Federal Register of January 20, 2015 (80 FR 2710), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. We received a total of 12 comments on the
guidance. Of these the following were related to the information
collection:
Two comments raised concerns regarding the possible difficulties
for manufacturers to submit a de novo for new accessories and for risk-
and regulatory control-based classification of accessories that were
approved under the premarket approval application (PMA) for the parent
medical devices. One comment questioned whether FDA considered the
possible ``practical and economic impact'' of the proposed definition
of ``accessories'' that may result in manufacturers being obligated to
list some components as accessories for FDA's registration and listing
process. The second comment anticipates that ``few companies are likely
to pursue this route given the associated costs and minimal advantage
in time to market.'' Neither comment specifically discusses the
potential PRA burden hours of voluntarily submitting a de novo
application; however, it may be inferred that this could impact their
resources under the PRA for submitting a de novo.
Also, FDA is not proposing to limit or remove any mechanism that
currently exists for manufacturers to obtain marketing authorization
for accessories. De novos are typically less burdensome than PMAs for
the purpose of classifying a new accessory. Furthermore, if a
manufacturer wishes for an accessory to remain in the same regulatory
class as the parent device, that manufacturer may continue to submit
the accessory for clearance or
[[Page 40316]]
approval under the submission type applicable to the parent device.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Accessory classification de novo request........................... 8 1 8 180 1,440
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Respondents are medical device manufacturers seeking to market
device accessories. Of the approximately 41 de novo applications
received per year, only 2 have been associated with accessories. With
heightened awareness of the availability of the de novo pathway for
accessories, we expect to receive four to six additional accessories
applications per year. Therefore, we estimate that we will receive
approximately eight accessory classification de novo requests per year.
Based on estimates by FDA administrative and technical staff who are
familiar with the proposed submission process for accessory
classification requests and on our burden estimate for a similar
information collection request (see ``De Novo Classification Process
Evaluation of Automatic Class III Designation; Draft Guidance for
Industry and Food and Drug Administration Staff; Availability,'' 79 FR
47651 at 47653, August 14, 2014), we estimate that the submission
process for each accessory classification request will take
approximately 180 hours.
The draft guidance also refers to previously approved collections
of information found in FDA regulations. The collections of information
in 21 CFR parts 801 and 809 have been approved under OMB control number
0910-0485; the collections of information in 21 CFR part 807, subpart E
have been approved under OMB control number 0910-0120; the collections
of information in 21 CFR part 814 have been approved under OMB control
number 0910-0231; and the collections of information in 21 CFR part
860, subpart C, have been approved under OMB control number 0910-0138.
Dated: June 15, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-14562 Filed 6-20-16; 8:45 am]
BILLING CODE 4164-01-P